Control of tumor growth via inhibition of tumor angiogenesis

Advances in Experimental Medicine and Biology

Volumn 451, Issue , 1998, Pages 57-61

  Plate, Karl H ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 0031784327     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-5357-1_9     Document Type: Article

References (28)

1. Folkman J, 1990; What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (82): 4-6
2. Gimbrone M.A, Jr., Leapman S B, Cotran R S, Folkman J, 1972; Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136: 261-276
3. Folkman J, Hanahan D, 1991; Expression of the angiogenic phenotype during development of murine and human cancer. In: Origins of human cancer: A comprehensive review. Cold Spring Harbor Laboratory Press, pp 803-814
4. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996
5. Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology 9: 630-634 (1991)
6. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S. Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhard, C., Desclerc, C., Pawling, M., Moons, L., Collen, D., Risau, W., and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996
7. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K., and Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996
8. Fong G-H, Rossant J, Gertsenstein M, Breitman ML: Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995
9. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Breitman ML, Schuh AC: Failure of bloodisland formation and vasculogenesis in flk-1 deficient mice. Nature 376: 62-66, 1995
10. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Quin Y (1995) Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 376: 70-74
11. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato N, Yancopoulos G. Requisite role of angiopoietin-1, a ligand for the tie2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996
12. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich T, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997
13. Plate KH, Breier G, Risau W (1994) Molecular mechanisms of developmental and tumour angiogenesis. Brain Pathol 4: 207-218
14. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 15: 339-347, 1995
15. Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thrombosis and Haemostasis 78: 678-683 (1997)
16. Plate KH. Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer & Metastasis Reviews 15: 237-240 (1996)
17. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989
18. Conolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470-1478, 1989
19. Keck PJ, Hauser S, Krivi G, Sanzo K, Warren T, Feder J, Conolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (246): 1309-1312, 1989
20. Alon T, Hemo I, Itin A, Peėr J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine (1): 1024-1028, 1995
21. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761-8766, 1997
22. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992
23. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992
24. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270:19761-19766, 1995
25. Levy, A.P., Levy, N.S., and Goldberg, M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271: 2746-2753, 1996
26. Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Research 57: 3860-3864, 1997
27. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams, LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992
28. Terman BC, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bšhlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Comm 187: 1579-1586, 1992